Cardiovascular Health

The Pharmacy Times® Cardiovascular Health resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
Study results have shown that a regimen of once-daily edoxaban (Lixiana, Daiichi Sankyo) combined with a P2Y12 inhibitor is noninferior to the current recommended treatment for patients with atrial fibrillation following successful percutaneous coronary intervention, and may result in less bleeding.
[[thumbnail_alt_text]]
The PHARM-CHF trial investigated whether regularly seeing a pharmacist improves adherence to heart failure medications.
[[thumbnail_alt_text]]
Transthyretin amyloid cardiomyopathy is a rare and fatal disease for which there are no previously approved treatments.
[[thumbnail_alt_text]]
Top news of the day from across the health care industry.
[[thumbnail_alt_text]]
As a result of the agreement, Teva is licensed to launch a generic version of liraglutide (Victoza, Novo Nordisk) as of December 22, 2023.
[[thumbnail_alt_text]]
The benefits of statin therapy for most people outweigh the risks.
[[thumbnail_alt_text]]
During a recent panel discussion, 5 pharmacists and physicians raised key points about reducing the cost of managing nonvalvular atrial fibrillation (NVAF).
[[thumbnail_alt_text]]
The data back earlier findings, published in the ROCKET-AF trial, which showed rivaroxaban-treated patients were better protected against more severe stroke and 30-day post-stroke mortality, compared to warfarin.
[[thumbnail_alt_text]]
Janssen's Xarelto (rivaroxaban) is now indicated for reducing the risk of major cardiovascular events, such as death, myocardial infarction, and stroke, in people with chronic coronary or peripheral artery disease.
[[thumbnail_alt_text]]
Gary M. Besinque, PharmD, FCSHP; Jaime E. Murillo, MD; Juvairiya Pulicharam, MD; and Peter Salgo, MD, discuss how real-world data surrounding the management of nonvalvular atrial fibrillation with novel oral anticoagulant therapy can be relayed back to various stakeholders, including drug manufacturers, to help to address gaps and improve outcomes for patients.
[[thumbnail_alt_text]]
Gary M. Besinque, PharmD, FCSHP; Jaime E. Murillo, MD; Juvairiya Pulicharam, MD; Ralph J. Riello III, PharmD, BCPS; and Peter Salgo, MD, consider why it is important for hospitals to establish a protocol for managing patients on novel oral anticoagulant therapy.
[[thumbnail_alt_text]]
Gary M. Besinque, PharmD, FCSHP; Jaime E. Murillo, MD; Juvairiya Pulicharam, MD; Ralph J. Riello III, PharmD, BCPS; and Peter Salgo, MD, discuss practical implications for using available novel oral anticoagulant therapy reversal agents in patients with nonvalvular atrial fibrillation.